Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | APG-3288 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on APG-3288, a putative BTK degrader (Mar 2026). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| APG-3288 | APG3288|APG 3288 | BTK inhibitor 39 | Limited information is currently available on APG-3288, a putative BTK degrader (Mar 2026). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07424833 | Phase I | APG-3288 | A Study of APG-3288 in Relapsed/Refractory Blood Cancers | Not yet recruiting | USA | 1 |